NEW YORK, Oct. 20, 2015 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") (NYSE: VRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
The investigation concerns whether Valeant and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On October 14, 2015, post-market, Valeant disclosed that it had been subpoenaed by U.S. prosecutors concerning the company's pricing, drug distribution and patient assistance programs.
On this news, the company's shares have fallen more than $22.00, or 12%, during intraday trading on October 15, 2015.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
SOURCE Pomerantz LLP